Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): Design and rationale of a randomized controlled trial by Wiggers, J.K. (Jimme K.) et al.
Wiggers et al. BMC Gastroenterology  (2015) 15:20 
DOI 10.1186/s12876-015-0251-0STUDY PROTOCOL Open AccessPreoperative endoscopic versus percutaneous
transhepatic biliary drainage in potentially
resectable perihilar cholangiocarcinoma (DRAINAGE
trial): design and rationale of a randomized
controlled trial
Jimme K Wiggers1†, Robert JS Coelen1†, Erik AJ Rauws2, Otto M van Delden3, Casper HJ van Eijck5,
Jeroen de Jonge5, Robert J Porte6, Carlijn I Buis6, Cornelis HC Dejong7, I Quintus Molenaar8, Marc GH Besselink1,
Olivier RC Busch1, Marcel GW Dijkgraaf4 and Thomas M van Gulik1*Abstract
Background: Liver surgery in perihilar cholangiocarcinoma (PHC) is associated with high postoperative morbidity
because the tumor typically causes biliary obstruction. Preoperative biliary drainage is used to create a safer environment
prior to liver surgery, but biliary drainage may be harmful when severe drainage-related complications deteriorate
the patients’ condition or increase the risk of postoperative morbidity. Biliary drainage can cause cholangitis/cholecystitis,
pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehydration. Two methods of preoperative
biliary drainage are mostly applied: endoscopic biliary drainage, which is currently used in most regional centers
before referring patients for surgical treatment, and percutaneous transhepatic biliary drainage. Both methods
are associated with severe drainage-related complications, but two small retrospective series found a lower incidence
in the number of preoperative complications after percutaneous drainage compared to endoscopic drainage (18-25%
versus 38-60%, respectively). The present study randomizes patients with potentially resectable PHC and biliary
obstruction between preoperative endoscopic or percutaneous transhepatic biliary drainage.
Methods/Design: The study is a multi-center trial with an “all-comers” design, randomizing patients between
endoscopic or percutaneous transhepatic biliary drainage. All patients selected to potentially undergo a major
liver resection for presumed PHC are eligible for inclusion in the study provided that the biliary system in the future
liver remnant is obstructed (even if they underwent previous inadequate endoscopic drainage). Primary outcome
measure is the total number of severe preoperative complications between randomization and exploratory laparotomy.
The study is designed to detect superiority of percutaneous drainage: a provisional sample size of 106 patients is
required to detect a relative decrease of 50% in the number of severe preoperative complications (alpha = 0.95;
beta = 0.8). Interim analysis after inclusion of 53 patients (50%) will provide the definitive sample size. Secondary
outcome measures encompass the success of biliary drainage, quality of life, and postoperative morbidity and mortality.
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Discussion: The DRAINAGE trial is designed to identify a difference in the number of severe drainage-related complications
after endoscopic and percutaneous transhepatic biliary drainage in patients selected to undergo a major liver resection for
perihilar cholangiocarcinoma.
Trial registration: Netherlands Trial Register [NTR4243, 11 October 2013].
Keywords: Perihilar cholangiocarcinoma, Resection, Preoperative biliary drainage, ComplicationsBackground
Perihilar cholangiocarcinoma (PHC) is a biliary malig-
nancy originating at or near the hepatic duct confluence
that typically causes biliary obstruction with concomi-
tant cholestasis [1]. Surgical resection of PHC, using a
combined extrahepatic bile duct resection and partial
liver resection, offers the best chance for long-term sur-
vival with a reported median survival of 19–39 months
in large series [2]. However, liver surgery in cholestatic
patients with PHC is associated with high risks of post-
operative morbidity and mortality, as reported up to
68% and 18%, respectively [3,4].
Preoperative biliary drainage is used to create a safer
environment for liver surgery in PHC [5]. It reduces
jaundice, improves nutritional status and liver function,
reduces bacterial translocation, and improves the ability
of the liver to regenerate postoperatively [6]. Owing to
these effects, preoperative biliary drainage has been
shown to reduce postoperative mortality, especially in
extended liver resections [7]. Nonetheless, biliary drain-
age can be harmful when drainage related complications
further deteriorate the patients’ condition or increase the
risk of postoperative morbidity [8-10]. These complica-
tions potentially outweigh the benefits of biliary drainage,
and should be minimized in order to optimize surgical
outcomes.
The two most commonly used drainage techniques are
endoscopic biliary drainage (EBD) or percutaneous trans-
hepatic biliary drainage (PTBD). EBD is often used to treat
symptoms of jaundice in regional centers before referral
to specialty centers for surgical management. However,
preoperative EBD in PHC is associated with a high rate of
complications such as cholangitis and pancreatitis. As an
alternative, PTBD reportedly has a high rate of technical
success and theoretically, is associated with a lower in-
cidence of cholangitis because there is no retrograde
bacterial contamination from the gut. Nonetheless,
other drawbacks have been reported of PTBD includ-
ing hemorrhage, catheter dislocation, and patient dis-
comfort. Only two small retrospective series (n = 68
and n = 101) have compared the incidence of pre-
operative complications, consistently reporting fewer
complications after PTBD compared to EBD (18-25%
versus 38-60%, respectively) [11,12]. These studies were
obviously flawed by their retrospective study design andheterogeneity in procedure-site (i.e. regional versus spe-
cialty center). Prospective studies are needed to confirm
the potential benefit of preoperative PTBD compared to
EBD.
The present study randomizes patients between pre-
operative EBD and PTBD. Patients are eligible for inclu-
sion when they have presumed PHC on imaging, when
they are selected to potentially undergo a major liver re-
section, and when they have biliary obstruction in the
future liver remnant (FLR). The study is based on an
“all-comers” design, so patients may also be included if
they require additional preoperative biliary drainage after
previous inadequate EBD in a regional center before re-
ferral. The primary outcome measure of the study focuses
on the total number of severe preoperative drainage-
related complications.Methods/Design
Study objectives
The aim of this study is to compare EBD and PTBD in
terms of the total number of preoperative severe drainage-
related complications (primary outcome), the success of
biliary drainage, quality of life, and postoperative morbid-
ity and mortality.Design
The present study is a multicenter randomized controlled
superiority trial. Patients are randomized to preoperative
EBD or PTBD by minimization using computer-generated
allocation (www.tenalea.net). The randomization proced-
ure is stratified for three factors, including: (attempted)
biliary drainage procedures before referral to the enrolling
center (drainage naïve versus drainage non-naive); the
level of bile duct involvement (Bismuth type 1, 2, 3A or
3B versus type 4); and enrolling center.Participating centers
Five specialty centers for PHC treatment in the Netherlands
are currently enrolling patients, including the Academic
Medical Center in Amsterdam, the Erasmus Medical Center
in Rotterdam, the University Medical Center Groningen, the
Maastricht University Medical Center, and the University
Medical Center Utrecht.
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This study is conducted in accordance with the principles
of the Declaration of Helsinki and the Dutch Medical
Research Involving Human Subjects Act. The medical
ethical committee of the Academic Medical Center in
Amsterdam approved the protocol on September 2, 2013.
An addendum to the protocol was approved March 5,
2014. Secondary approval was sought from all local
ethics committees. Informed consent is obtained from
each participating patient in oral and written form
prior to randomization. The DRAINAGE trial is regis-
tered in the Dutch Trial Register with identification
number NTR4243.
Study population
The study is based on an “all-comers” design. All pa-
tients with presumed PHC, who are selected by the
multidisciplinary team meeting at one of the enrolling
centers to potentially undergo a major liver resection,
are eligible for inclusion in the study when they have bil-
iary obstruction in the FLR.
Inclusion criteria
According to the 7th edition of the American Joint
Committee on Cancer staging, PHC is defined as a
tumor originating in the common hepatic duct, the hep-
atic duct confluence, or in the left or right hepatic duct.
[1]. The latter category may also include patients with
an intrahepatic tumor that invades the hepatic duct con-
fluence. Pathologic confirmation of PHC is not required
prior to inclusion in the study. Patients are selected to
potentially undergo a major liver resection if preopera-
tive imaging with CT and/or MRCP shows a resectable
tumor without evidence of distant metastases (including
lymph node metastases beyond the hepatoduodenal liga-
ment) [1]. Portal vein resection and reconstruction may
be required to obtain tumor-free resection margins.
Biliary obstruction in the FLR is separately defined for pa-
tients with or without previous EBD procedures (Table 1).
For drainage naïve patients, it is defined as a total bilirubin
level of at least 50 μmol/L. For patients with previous EBD
procedures, it is defined as a persistently rising totalTable 1 Definitions of biliary obstruction in the future
liver remnant
Patient type Definition of inadequate biliary drainage
Drainage naïve Serum Bilirubin >50 μmol/L.
Drainage non-naïve Persistently rising total bilirubin level
above 50 μmol/L (i.e. no stent placed
or insufficient draining stent).
Persistent biliary dilatation in the FLR
on imaging (i.e. previous stent placed
in contralateral side of liver).
Patients are ‘drainage non-naïve’ if they underwent previous (attempted) EBD
before referral to one of the enrolling centers.bilirubin level above 50 μmol/L (i.e. no stent placed or in-
sufficiently draining stent) or as persistent biliary dilatation
in the FLR on imaging (i.e. previous stent placed in contra-
lateral side of liver).
Exclusion criteria
Since the primary outcome measure focuses on compli-
cations, patients are not eligible for inclusion if they
have incompletely recovered from any side effect of pre-
vious biliary drainage procedures. Patients are required
to be off antibiotic treatment for at least 5 days. Other ex-
clusion criteria include any contra-indication for major liver
surgery (e.g. ECOG/WHO score ≥3), technical contra-
indication for either EBD or PTBD (e.g. previous gastrojeju-
nostomy), or refusal to provide informed consent.
Primary outcome measure
The primary outcome is the total number of severe drainage-
related complications measured between randomization
and exploratory laparotomy. The study is designed to de-
tect superiority of PTBD. Some patients lose eligibility to
undergo major liver resection before exploratory laparot-
omy (e.g. distant metastases found at staging laparoscopy,
deterioration of the patients’ condition, or diagnosis of be-
nign disease precluding the need for surgical therapy). For
these patients, the number of drainage-related complica-
tions is measured until 7 days after the decision to cancel
exploratory laparotomy, or until 90 days after randomization
(whichever comes first).
A severe complication is defined as any complication
related to the drainage procedures, leading to an add-
itional invasive intervention, (extended) hospitalization,
or death. Definitions for potential severe drainage-related
complications, as evaluated in previous studies, [11,13] are
shown in Table 2.
To exclude bias in determining events pertaining to
the primary outcome measure, a blinded adjudication
committee will review all events and evaluate whether
events count as severe complication according to the
proposed definitions.
Secondary outcome measures
Secondary outcome measures will be used to select the
preferred method if there is no difference in the primary
outcome at conclusion of the study. Secondary outcome
measures include:
– The separate incidence of preoperative cholangitis;
– The number of drainage procedures required to
achieve technical success;
– The proportion of patients with therapeutic success
at 7 days after technical success;
– The total number of drainage procedures that
involved (attempted) stent (re-) placement;
Table 2 Definitions of severe complications in the primary outcome measure
Severe complication Criteria
Cholangitis Elevation in temperature more than 38,5°C and Leukocytes ≥10 *109/L, thought to have a biliary cause, without
concomitant evidence of acute cholecystitis, requiring invasive intervention.
Acute cholecystitis Radiologic evidence of cholecystitis, elevation in temperature more than 38.5°C and Leukocytes ≥10*109/L, and
requirement of percutaneous drainage or emergency cholecystectomy.
Stent/ catheter dysfunction Rising bilirubin level after therapeutic success had initially been obtained, without signs of cholangitis or
cholecystitis, requiring new cannulation of the tumor.
Acute pancreatitis Abdominal pain and a serum concentration of pancreatic enzymes (amylase or lipase) ≥3 times the upper limit
of normal, that requires ≥1 one night of hospitalization.
Hemorrhage Clinical evidence of bleeding with the need of a blood transfusion.
Perforation Retroperitoneal or bowel-wall perforation documented by any radiographic technique requiring intervention.
Portal vein thrombosis Clinical evidence of thrombosis confirmed on colour Doppler US as absence of flow compatible with occlusion,
precluding liver surgery.
Dehydration Severe dehydration with electrolyte disturbances resulting from excessive fluid loss through externally draining
catheters, requiring rehydration in the clinical setting.
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treatment;
– Interval bilirubin decrease at 7 days and 14 days
after biliary drainage relative to the bilirubin level at
randomization;
– The number of patients with rescheduled or
cancelled laparotomy due to severe drainage-related
complications;
– Quality of life, measured with the EORTC Quality of
Life Questionnaire C-30 (QLQ-C30) and its biliary
cancer module (QLQ-BIL21);ble 3 Definitions of postoperative morbidity and mortality
ent Criteria
stoperative mortality Any reason of death wit
stoperative morbidity
sthepatectomy liver failure Increasing INR and biliru
management (Grade B d
[ISGLS]) [14].
olangitis Elevation in temperature
cause, without concomi
paticojejunostomy (biliary) leakage Drainage of fluid with a
or after postoperative da
or biliary peritonitis; or d
ISGLS) [15].
tra-abdominal abscess formation Intra-abdominal fluid co
tomography, associated
ound infection Requiring intervention; o
rtal vein thrombosis Conclusive radiologic ev
morrhage A drop in haemoglobin
baseline level and/or po
falling haemoglobin and
re-laparotomy to stop b
ergency re-laparotomy Any (other) reason follow
eumonia Pulmonary infection wit– Postoperative morbidity and mortality, as defined in
Table 3, among patients who underwent combined
extrahepatic bile duct and major liver resection. The
International Study Group of Liver Surgery (ISGLS)
definitions for post-hepatectomy liver failure, bile
leakage and hemorrhage are used [14-16].
Study outline
The general study outline is presented in Figure 1. All
patients with presumed PHC presenting at the partici-
pating centers are evaluated in a multidisciplinary teamhin 90 days after major liver resection.
bin on or after postoperative day 5 plus deviation from regular clinical
efinition according to the International Study Group of Liver Surgery
more than 38.5°C and Leukocytes ≥10*109/L, thought to have a biliary
tant evidence of acute cholecystitis, requiring invasive intervention [13].
n increased bilirubin level three times greater than the serum level on
y three; or the need for interventions as the result of bile collections
irect visual evidence of defect at anastomoses (definition according to
llection with positive cultures identified by ultrasonography or computed
with persistent fever and elevations of white blood cells [13].
therwise considered as minor complication [13].
idence of thrombosis [13].
level >3 g/dl post-operatively compared with the post-operative
st-operative transfusion of ≥2 units packed red blood cells for a
/or the need for radiological intervention (such as embolization) and/or
leeding (Grade B/C haemorrhage according to ISGLS) [16].
ing major liver resection [13].
h radiological confirmation and requiring antibiotic treatment [13].
Figure 1 Flowchart of the study.
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exclusion criteria are met according to the multidiscip-
linary team meeting based on clinical history and CT
and/or MRCP imaging. Next, the type of liver resection
indicated is determined in the multidisciplinary team
meeting, defining the side of the FLR and primary aim
of preoperative biliary drainage. Planned liver resections
may consist of right (extended) hemihepatectomy, left
extended hemihepatectomy, or left hemihepatectomy:
the corresponding FLR that should be drained preopera-
tively consists of the left liver segments, the right poster-
ior segments, or the right anterior + posterior segments.
After informed consent has been obtained, patients
are randomized to undergo EBD or PTBD of the FLR
within 5 days. The allocated drainage procedure shouldbe repeated until internal biliary drainage of the FLR has
been achieved (i.e. technical success). Follow-up is done
at 7 days after technical success: therapeutic success at
follow-up is defined as normal caliber bile ducts in the
FLR on ultrasonography and a minimum 20% decrease
in the total bilirubin level compared to the reference
level at randomization. Additional total bilirubin assess-
ments are performed at 14 days after technical success,
and at admission for exploratory laparotomy, to evaluate
patency of the biliary drainage. Revisional drainage pro-
cedures may be required if complications occur after bil-
iary drainage, as described in Table 2. Complications are
treated according to local guidelines. Crossover treatment
is allowed if the allocated drainage procedure is consid-
ered to be no longer technically feasible (e.g. cholangitis
Table 4 The estimated number of complications in each
study group used to calculate the provisional sample size
EBD PTBD
0 complications 50% 75%
1 complication 25% 17%
≥2 complications 25% 8%
Total proportion 100% 100%
The estimated proportion of patients is presented for each categorical number
of complications.
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itional PTBD).
Additional staging (e.g. percutaneous biopsy or staging
laparoscopy) may be used to further determine resectabil-
ity of the tumor after randomization and initial biliary
drainage. Patients who loose eligibility to undergo major
liver resection because distant metastases are found at
additional staging remain included in the intention-to-
treat analysis, as described above.
Exploratory laparotomy is intentionally scheduled
at 4 weeks after randomization, or at 6 weeks after
randomization if the patient requires portal vein
embolization. A radical resection is pursued at explora-
tory laparotomy if the diagnosis of resectable PHC
without distant metastases is confirmed. Resections consist
of excision of the liver hilum en bloc with (extended) hemi-
hepatectomy including the caudate lobe, and complete
lymphadenectomy of the hepatoduodenal ligament. Portal
vein excision and reconstruction are used when necessary.
If present, transhepatic percutaneous drains are left in-situ
and used as transanastomotic drains to facilitate healing of
the hepaticojejunostomies.
Preoperative biliary drainage
Technical success of biliary drainage is defined as suc-
cessful stent/catheter placement providing internal bil-
iary drainage of the future liver remnant. Preoperative
biliary drainage preferably consists of unilateral drainage
of the FLR, but bilateral drainage may be indicated as
evaluated by the treating physician (e.g. need for portal
vein embolization or bilateral cholangitis) [17].
Endoscopic biliary drainage
A sphincterotomy with blended electrosurgical current
may be used to facilitate the insertion of multiple stents
and/or brush cytology. Opacification upstream of the
obstruction is intentionally restricted to segments that
are aimed to be drained during the procedure. Bile duct
(s) unintentionally opacified upstream from the obstruc-
tion should be drained during the same procedure. Poly-
ethylene endoprostheses (size 10Fr) are then pushed in
position over the catheter. Directly after the procedure,
a 100 mg Diclofenac suppository is administered to the
patient for the prevention of post ERCP-pancreatitis [18].
Percutaneous transhepatic biliary drainage
The technique of PTBD involves the use of ultrasound
guidance, a thin Chiba needle and a 0.014-inch guidewire
to gain access to the biliary system. Antegrade cholangiog-
raphy will be used to localize the site of obstruction. The
guidewire is manoeuvred through the stenosis. A catheter
is placed with its distal end in the duodenum for internal-
external-drainage. Externally draining bile is collectedapproximately during the first 48 h, after which the cath-
eter is closed in order to achieve internal drainage.
Antibiotic treatment
Standard antibiotic prophylaxes are administered at the
start of each biliary drainage procedure, according to local
protocol as described in an additional file [see Additional
file 1]. Prophylactic antibiotic protocols vary between cen-
ters, but they are similar for EBD and PTBD procedures
in the same center.
Data collection and monitoring
All preoperative and postoperative complications will be
monitored. Patients complete questionnaires (QLQ-C30/
BIL21) at the day of randomization, and at 7 days,
28 days, and 90 days after randomization. There will be
regular contact between the trial coordinator and the
participating centers. Baseline and outcome data are col-
lected by designated data managers using a standardized
case record form [see Additional file 2], which is moni-
tored by the trial coordinator.
Statistical analysis
The DRAINAGE trial is a superiority trial, designed to de-
tect a reduction in the primary outcome measure in favor
of PTBD. The analysis will be based on the intention-to-
treat principle.
Sample size
Determination of the sample size is split in a provisional
and definitive calculation, because only little retrospect-
ive evidence is currently available for power estimation.
A previous study from the primary study center showed
a severe complication rate of 60% in the EBD group ver-
sus 18% in the PTBD group. In the DRAINAGE trial, a
complication rate of 50% is expected after EBD and 25%
after PTBD (i.e. a relative decrease of 50%). This estima-
tion was further expanded with proportions for the
number of complications, as shown in Table 4. Account-
ing for a 3% dropout, 53 patients are needed in each
arm resulting in a provisional required sample size of
106 patients (Wilcoxon/Mann–Whitney rank-sum test
for ordered categories; α = 0.95; β = 0.8).
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will provide the definitive sample size, which will be cal-
culated based on the observed number of complications
in the EBD group. The definitive sample size will be de-
termined similar to the provisional sample size, again
using a relative decrease of 50% in the proportion of
complications unless the absolute decrease drops below
20%, which is defined as the lowest absolute decrease
with clinical relevance.
Data analysis
The principal analysis consists of an intention-to-treat
comparison of the number of preoperative severe drainage-
related complications. The research hypothesis will be eval-
uated using a Wilcoxon/Mann–Whitney rank-sum test
with a two-sided 0.05 significance level. The comparison
will be expressed in terms of a relative risk and 95% confi-
dence intervals, as determined with multinomial logistic
regression.
Subsequent analyses are directed at the secondary end-
points. Continuous data will be presented as the mean
with standard deviation or median with interquartile
range depending on data distribution, and accordingly
evaluated with Mann–Whitney U or t-test statistics. Cat-
egorical variables will be evaluated using Pearson’s chi-
squared test or Fisher’s Exact test as applicable.
Preplanned subgroup analyses will be based on a di-
chotomized complication rate to retain statistical power
(no complication versus 1 or more complications), and
the analyses will consist of logistic regression with the
subgroup and randomized treatment added as an inter-
action term. Subgroup analysis will be performed for pa-
tients with Bismuth type 4 tumors, and patients with a
left-sided FLR.
Safety
An independent data safety monitoring board (DSMB),
consisting of three independent specialists (surgeon,
gastroenterologist, clinical epidemiologist) will evaluate
the progress of the trial and examine the unblinded safety
variables (serious adverse events, patients completing
study follow-up) after 50% of inclusion (53 patients). The
DSMB will assist and advise the principal investigators so
as to protect the validity and credibility of the trial. Fur-
thermore, annual unblinded safety reports, including all
serious adverse events per group, are provided to the insti-
tutional review board.
Discussion
Preoperative biliary drainage in PHC is a technically dif-
ficult procedure, associated with a high risk of severe
drainage-related complications that may deteriorate the
patients’ condition or increase the risk of postoperative
morbidity and mortality after liver surgery. The majorityof patients referred for surgical treatment have already
undergone EBD procedures with attempted stent place-
ment upon referral. However, preoperative EBD in PHC
is associated with a high rate of complications: technical
failures may occur because proximal tumors at the liver
hilum are difficult to cannulate endoscopically; cholan-
gitis may occur because isolated bile ducts with segmen-
tal obstruction may be left undrained after contrast
injection; and pancreatitis may occur after repeated at-
tempts at contrast injection. As an alternative, PTBD
has a high rate of technical success because it offers se-
lective segmental drainage, and it has a theoretically
lower incidence of cholangitis because there is no retro-
grade bacterial contamination from the gut. Percutaneous
drains also have the potential advantage of protecting
hepaticojejunostomies from leaking postoperatively. None-
theless, PTBD is associated with other drawbacks, includ-
ing hemorrhage from perforated liver parenchyma, bile
leakage, catheter dislocation, and patient discomfort. The
DRAINAGE trial is designed to answer the question if pre-
operative PTBD is associated with fewer preoperative se-
vere drainage-related complications compared to EBD.
Although PTBD is often in used in Western specialty
centers, it has been associated with seeding metastases in
2-5% of patients after resection of PHC [12,19-21]. Conse-
quently, most Eastern specialty centers chose to use pre-
operative endoscopic nasobiliary drainage (ENBD) as their
preferred method, after its efficacy was consolidated in a
large series of 164 patients [22]. Nonetheless, Western
centers generally decline to use ENBD because it severely
impairs patients’ quality of life. ENBD stents drain bile ex-
ternally through a gastro-duodenal tube, and require bile
suppletion either via the oral route or via a second gastro-
duodenal tube. Moreover, an association with seeding me-
tastases may not be limited to PTBD, as previous series
have also shown seeding metastases after endoscopic
drainage methods [23]. The DRAINAGE trial is designed
to identify PTBD as the preferred preoperative drainage
method despite the reported incidence of seeding metasta-
ses, because a negative effect of PTBD on survival after re-
section of PHC has insufficiently been shown.
The rarity of PHC complicates accrual of a sufficient
number of patients in a randomized controlled trial. To
overcome this challenge, all centers that specialize in
surgical treatment of PHC in the Netherlands participate
in the DRAINAGE trial, making it a nationwide study.
The chosen “all-comers” design, which allows patients to
be included in the study even if they underwent previous
inadequate drainage procedures in regional centers be-
fore referral, will also improve the patient accrual. More-
over, this study design provides pragmatic results to
answer the question how to treat any patient that pre-
sents with potentially resectable PHC and biliary ob-
struction in the future liver remnant.
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Additional file 1: Antibiotics protocol. Prophylactic antibiotics
protocol among participating centers in DRAINAGE trial. This additional
file describes the prophylactic antibiotics protocol in all centers that
participate in the DRAINAGE trial.
Additional file 2: Case record form DRAINAGE Trial. This additional
file is the standardized case record form (CRF) of the DRAINAGE trial
which is used to collect all baseline and outcome data by designated
data managers.
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